{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:08:01Z","timestamp":1761523681258},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1477-7819-12-35","type":"journal-article","created":{"date-parts":[[2014,2,11]],"date-time":"2014-02-11T14:01:54Z","timestamp":1392127314000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A case report on efficacy of Abound\u2122 for anti-EGFR antibody-associated skin disorder in metastatic colon cancer"],"prefix":"10.1186","volume":"12","author":[{"given":"Nobuhisa","family":"Matsuhashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Nonaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kengo","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Yawata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Tanahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Imai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Osada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,2,11]]},"reference":[{"key":"1537_CR1","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s00520-008-0403-7","volume":"16","author":"L Berk","year":"2008","unstructured":"Berk L, James J, Schwartz A, Hug E, Mahadevan A, Samuels M, Kachnic L, RTOG: A randomized, double-blind, placebo-controlled trial of a \u03b2-hydroxyl \u03b2-methyl butyrate, glutamine, and argininemixture for the treatment of cancer cachexia (RTOG 0122). Support Care Cancer. 2008, 16: 1179-1188. 10.1007\/s00520-008-0403-7.","journal-title":"Support Care Cancer"},{"key":"1537_CR2","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.clnu.2005.01.006","volume":"24","author":"S Marcoraa","year":"2005","unstructured":"Marcoraa S, Lemmeya A, Maddisona P: Dietary treatment of rheumatoid cachexia with b-hydroxy-b-methylbutyrate, glutamine andarginine: a randomised controlled trial. Clin Nutr. 2005, 24: 442-454. 10.1016\/j.clnu.2005.01.006.","journal-title":"Clin Nutr"},{"issue":"31","key":"1537_CR3","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","volume":"28","author":"JY Douillard","year":"2010","unstructured":"Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Koc\u00e1kova I, Ruff P, B\u0142asi\u0144ska-Morawiec M, \u0160makal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J: Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010, 28 (31): 4697-4705. 10.1200\/JCO.2009.27.4860.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1537_CR4","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1200\/JCO.2007.14.7116","volume":"26","author":"RG Amado","year":"2008","unstructured":"Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008, 26 (10): 1626-1634. 10.1200\/JCO.2007.14.7116.","journal-title":"J Clin Oncol"},{"issue":"31","key":"1537_CR5","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1200\/JCO.2009.27.6055","volume":"28","author":"M Peeters","year":"2010","unstructured":"Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, Andr\u00e9 T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, Tzekova V, Collins S, Oliner KS, Rong A, Gansert J: Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol. 2010, 28 (31): 4706-4713. 10.1200\/JCO.2009.27.6055.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1537_CR6","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S1470-2045(05)70102-9","volume":"6","author":"M Moroni","year":"2005","unstructured":"Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta M, Siena S, Bardelli A: Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 2005, 6 (5): 279-286. 10.1016\/S1470-2045(05)70102-9.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1537_CR7","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1093\/annonc\/mdj084","volume":"17","author":"G Folprecht","year":"2006","unstructured":"Folprecht G, Lutz MP, Sch\u00f6ffski P, Seufferlein T, Nolting A, Pollert P, K\u00f6hne CH: Cetuximab and irinotecan\/5-fluorouracil\/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol. 2006, 17 (3): 450-456. 10.1093\/annonc\/mdj084.","journal-title":"Ann Oncol"},{"issue":"6 Suppl 9","key":"1537_CR8","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1053\/j.seminoncol.2005.04.029","volume":"32","author":"N Personeni","year":"2005","unstructured":"Personeni N, Hendlisz A, Gallez J, Galdon MG, Larsimont D, Van Laethem JL, Nagy N, Barette M, Paesmans M, Cardoso F, Bleiberg H: Correlation between the response to cetuximab alone or in combination with irinotecan and the activated\/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer. Semin Oncol. 2005, 32 (6 Suppl 9): S59-S62.","journal-title":"Semin Oncol"},{"issue":"8","key":"1537_CR9","doi-asserted-by":"publisher","first-page":"3992","DOI":"10.1158\/0008-5472.CAN-06-0191","volume":"66","author":"A Li\u00e8vre","year":"2006","unstructured":"Li\u00e8vre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, C\u00f4t\u00e9 JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F, Laurent-Puig P: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006, 66 (8): 3992-3995. 10.1158\/0008-5472.CAN-06-0191.","journal-title":"Cancer Res"},{"issue":"2","key":"1537_CR10","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1159\/000229752","volume":"77","author":"X Su","year":"2009","unstructured":"Su X, Lacouture ME, Jia Y, Wu S: Risk of high-grade skin rash in cancer patients treated with cetuximab \u2013 an antibody against epidermal growth factor receptor: systemic review and meta-analysis. Oncol. 2009, 77 (2): 124-133. 10.1159\/000229752.","journal-title":"Oncol"},{"issue":"1","key":"1537_CR11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/S1470-2045(10)70278-3","volume":"12","author":"U Gatzemeier","year":"2011","unstructured":"Gatzemeier U, von Pawel J, Vynnychenko I, Zatloukal P, de Marinis F, Eberhardt WE, Paz-Ares L, Schumacher KM, Goddemeier T, O\u2019Byrne KJ, Pirker R: First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study. Lancet Oncol. 2011, 12 (1): 30-37. 10.1016\/S1470-2045(10)70278-3.","journal-title":"Lancet Oncol"},{"key":"1537_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S1470-2045(11)70318-7","volume":"13","author":"R Pirker","year":"2012","unstructured":"Pirker R, Pereira JR, von Pawel J, Krzakowski M, Ramlau R, Park K, de Marinis F, Eberhardt WE, Paz-Ares L, St\u00f6rkel S, Schumacher KM, von Heydebreck A, Celik I, O'Byrne KJ: EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol. 2012, 13: 33-42. 10.1016\/S1470-2045(11)70318-7.","journal-title":"Lancet Oncol"},{"issue":"34","key":"1537_CR13","doi-asserted-by":"publisher","first-page":"5390","DOI":"10.1200\/JCO.2007.12.6987","volume":"25","author":"A Scope","year":"2007","unstructured":"Scope A, Agero AL, Dusza SW, Myskowski PL, Lieb JA, Saltz L, Kemeny NE, Halpern AC: Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol. 2007, 25 (34): 5390-5396. 10.1200\/JCO.2007.12.6987.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1537_CR14","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/S0002-9610(02)00823-1","volume":"183","author":"PE May","year":"2002","unstructured":"May PE, Barber A, D\u2019Olimpio JT, Hourihane A, Abumrad NN: Reversal of cancer-related wasting using oral supplementation with a combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine. Am J Sur. 2002, 183 (4): 471-479. 10.1016\/S0002-9610(02)00823-1.","journal-title":"Am J Sur"},{"issue":"3","key":"1537_CR15","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1097\/00000658-200209000-00013","volume":"236","author":"JZ Williams","year":"2002","unstructured":"Williams JZ, Abumrad N, Barbul A: Effect of a specialized amino acid mixture on human collagen deposition. Ann Surg. 2002, 236 (3): 369-375. 10.1097\/00000658-200209000-00013.","journal-title":"Ann Surg"},{"issue":"3","key":"1537_CR16","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1177\/0148607100024003133","volume":"24","author":"RH Clark","year":"2000","unstructured":"Clark RH, Feleke G, Din M, Yasmin T, Singh G, Khan FA, Rathmacher JA: Nutritional treatment for acquired immunodeficiency virus-associated wasting using beta-hydroxy beta-methylbutyrate, glutamine, and arginine: a randomized, double-blind, placebo-controlled study. JPEN J Parenter Enteral Nutr. 2000, 24 (3): 133-139. 10.1177\/0148607100024003133.","journal-title":"JPEN J Parenter Enteral Nutr"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1477-7819-12-35.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T02:54:05Z","timestamp":1630551245000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/1477-7819-12-35"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,11]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["1537"],"URL":"https:\/\/doi.org\/10.1186\/1477-7819-12-35","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,11]]},"assertion":[{"value":"8 September 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"35"}}